A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Introduction: BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non-overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. Methods: In this multicenter, phase 1, 3+3 dose-escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28-day ibrutinib run-in (420 mg daily), then added lenalidomide with intra-patient escalation to a cohort-assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Results: Twenty-seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow-up of 50.4 months, median progression-free survival was 69.5 months (95% CI 53.4-NE). Conclusion: Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. Trial Registration: ClinicalTrials.gov identifier: NCT01886859.
Source: eJHaem
DOI: 10.1002/jha2.70463
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,860
Funder: National Cancer Institute
Award: G9001373046
OpenAlex ID: W7234296910
